CTOs on the Move

Antios Therapeutics

www.antiostherapeutics.com

 
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Antios Therapeutics raised $25M on 11/27/2018
Antios Therapeutics raised $75M on 11/03/2021

Similar Companies

VelosBio

VelosBio Inc. is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer. Its lead candidate, VLS-101, is a ROR1-directed ADC being developed for patients with hematologic and solid tumor malignancies. The company is developing a broad pipeline of therapeutics targeting ROR1 in oncologic indications with high unmet medical need.

Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children.

Genome International Corporation

Genome International Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EduQuest

EduQuest is a Clarksburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ensysce Biosciences

Ensysce Biosciences, San Diego, CA, is a clinical stage private biopharma with prodrug platforms that address opioid use disorder. Trypsin-Activated Abuse Protection (TAAP) technology forms an opioid prodrug that can only be activated through a 2-step internal digestive process, and therefore cannot be abused by chewing, snorting or IV administration.